to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
See who made this week's list
Ronald Lindsay, CEO of Zebra Biologics Inc., thinks changes in the biotech industry will lead to a trend of success for biotech companies. His company’s technology can be used as a platform to discover and develop bio-superior antibody therapeutics and complex drug targets. Zebra has just pulled in $9 million in its first investing round, and Lindsay thinks one of the biggest changes for the future of biotech is the availability of venture funding.
At a Life Science Ventures Summit hosted by the Kauffman Foundation, Huffington Post writer Jennifer Hill led a discussion focused on the players in entrepreneurship. The presentation opened with experienced entrepreneurs giving their thoughts on the idea of team building. (00:00-01:19)
A well-established business model is important for any startup, but it becomes even more vital for startups developing platform technology. IRISense CEO Brent Cousino said his company had multiple value propositions for his innovation that have provided different expansion paths of success.
At the core of any startup company is the idea. The idea is the true value of a company, according to LIM Innovations CEO and co-founder Andrew Pedtke, and he says protecting that idea should be a main priority.
Paul Yock of Stanford's Biodesign and Jay Watkins of De Novo Ventures led a discussion with Marie Johnson, Darin Buxbaum, Brian Fahey and Peggy McLaughlin on the topic of clinical and regulatory strategy at a recent Life Science Ventures Summit hosted by the Kauffman Foundation (0:25:21-0:33:52).
A Life Science Ventures Summit hosted by the Kauffman Foundation provided advice on funding strategies for diagnostic startups (0:30:25-0:35:38). Diana Kander of Kander Rigby led a panel with Una Ryan, Tito Serafini, Risa Stack, Zen Chu and Jill Carroll.
DioGenix, in Gaithersburg, Md., was founded in 2009 after CEO Larry Tiffany and his senior management team saw a clear clinical need: monitoring disease progression of multiple sclerosis (MS). Tiffany has an extensive background in biotech, as an IP attorney, and as a senior executive at small and mid-size biotech companies. Before DioGenix, he was senior vice president and general manager of genomics for another genomics research company, Gene Logic.
Three years ago, Jason Bhan, MD, a family practitioner, went into business with a cousin—Sundeep Bhan, a serial entrepreneur—and a friend, Destry Sulkes, also an MD. The three healthcare entrepreneurs founded Medivo, which developed tools to track symptoms, explain lab results, and provide personalized health information.
Dr. Todd O’Brien has additional challenges beyond those encountered by most startup life science CEOs. The 48-year-old podiatrist still sees patients even while developing his latest innovation: an electronic tuning fork for measuring diabetes-related nerve damage in people’s feet. He's also building his company in Orono, Maine - far from any major healthcare hub.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.